arrakis therapeutics | Arrakis - Arrakis Therapeutics

Keyword	CPC	PCC	Volume	Score	Length of keyword
arrakis therapeutics	2	0.1	2673	59	20
arrakis	0.27	1	8573	69	7
therapeutics	0.59	0.2	2114	28	12

Keyword	CPC	PCC	Volume	Score
arrakis therapeutics	0.78	0.5	4899	92
arrakis therapeutics myc	0.51	0.8	5872	88
arrakis therapeutics stock	1.88	1	3224	88
arrakis therapeutics news	0.5	0.6	2322	37
arrakis therapeutics layoffs	1.52	0.9	1239	100
arrakis therapeutics address	0.02	0.6	4628	97
arrakis therapeutics careers	1.31	0.2	7616	80
arrakis therapeutics waltham ma	0.21	0.4	9546	29
arrakis therapeutics inc	0.71	0.5	9524	77
arrakis therapeutics zoominfo	1.58	0.9	7813	45
biotech startups arrakis therapeutics	0.78	0.4	1540	100

Search Results related to arrakis therapeutics on Search Engine

Arrakis - Arrakis Therapeutics
arrakistx.com

https://arrakistx.com/

WebWe are pioneering a new world of rSM medicines, ourselves and with partners. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics. JOIN THE EXPEDITION.

DA: 95 PA: 95 MOZ Rank: 56

Arrakis Therapeutics - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Arrakis_Therapeutics

Webwww .arrakistx .com. Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. [1] [2] The company is based in Waltham, Massachusetts, and was founded in 2015 by Jennifer Petter, now the company's Chief Innovation Officer.

DA: 5 PA: 15 MOZ Rank: 37

About Us - Arrakis Therapeutics
arrakistx.com

https://arrakistx.com/about/about-us/

WebAbout Us. At Arrakis, we are on an expedition to unlock the biology of RNA to discover new medicines for millions of people. We are discovering ways to target the RNA lifecycle – which is upstream of all biology – to find new points of therapeutic intervention. Our drug discovery tools are inventive yet practical, as we have re‑engineered ...

DA: 83 PA: 62 MOZ Rank: 59

Pipeline - Arrakis Therapeutics
arrakistx.com

https://arrakistx.com/pipeline/

WebArrakis has a pipeline of RNA-targeted drug programs that show promise for addressing a range of diseases, including cancer, cardiovascular conditions, neurodegeneration and rare diseases. In addition to wholly-owned programs for rSM medicines in our internal pipeline, we are establishing collaborations with large biopharmaceutical partners to ...

DA: 32 PA: 85 MOZ Rank: 33

Arrakis Therapeutics | LinkedIn
linkedin.com

https://www.linkedin.com/company/arrakis-therapeutics

WebWaltham, MA 10,216 followers. Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions of patients. View all 106 employees. About us. Arrakis has a...

DA: 80 PA: 45 MOZ Rank: 53

Arrakis Therapeutics Announces $75 Million Series B Financing …
arrakistx.com

https://arrakistx.com/news/press-releases/arrakis-therapeutics-announces-75-million-series-b-financing-to-advance-a-new-class-of-small-molecule-medicines-targeting-rna/

WebWaltham, Mass., April 18, 2019 – Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, has completed a $75 million Series B financing co-led by venBio Partners and Nextech Invest, with participation by new investors Omega Funds, HBM Healthcare ...

DA: 39 PA: 100 MOZ Rank: 5

First small-molecule drug targeting RNA gains momentum
nature.com

https://www.nature.com/articles/s41587-020-00788-1.pdf

Web“If you want to access new biology, you have to access new targets,” says Arrakis Therapeutics founder and CSO Jennifer Petter. The universe of potential targets includes non-coding RNAs too....

DA: 84 PA: 19 MOZ Rank: 37

Amgen and Arrakis Therapeutics Announce Multi-Target …
arrakistx.com

https://arrakistx.com/news/press-releases/amgen-and-arrakis-therapeutics-announce-multi-target-collaboration-to-identify-novel-rna-degrader-small-molecule-therapeutics/

WebArrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.

DA: 77 PA: 34 MOZ Rank: 59

A new drug approval for the vanguard of RNA ... - Arrakis Therapeutics
arrakistx.com

https://arrakistx.com/a-new-drug-approval-for-the-vanguard-of-rna-targeted-small-molecules/

WebAug 27, 2020 · A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. We have overcome many obstacles on this mission, inventing new concepts and methods where necessary and re-engineering known concepts and methods where possible. But we have not been the …

DA: 3 PA: 13 MOZ Rank: 38

Expedition RNA - Arrakis Therapeutics
arrakistx.com

https://arrakistx.com/about/expedition-rna/

WebArrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.

DA: 38 PA: 40 MOZ Rank: 57